Skip to content
Chloroquine
Aralen (chloroquine) is a small molecule pharmaceutical. Chloroquine was first approved as Aralen hydrochloride on 1982-01-01. It is used to treat amebiasis, avian malaria, discoid lupus erythematosus, falciparum malaria, and malaria amongst others in the USA. It is known to target mas-related G-protein coupled receptor member X1 and prosaposin.
Download report
Favorite
COVID-19
Case Study: COVID-19
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
musculoskeletal diseasesD009140
skin and connective tissue diseasesD017437
immune system diseasesD007154
animal diseasesD000820
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Chloroquine hydrochloride
Tradename
Company
Number
Date
Products
ARALEN HYDROCHLORIDESanofiN-006002 DISCN1982-01-01
1 products
Hide discontinued
Chloroquine phosphate
Tradename
Company
Number
Date
Products
ARALENSanofiN-006002 DISCN1982-01-01
1 products, RLD
Hide discontinued
Chloroquine phosphate
+
Primaquine phosphate
Tradename
Company
Number
Date
Products
ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATESanofiN-014860 DISCN1982-01-01
1 products
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
chloroquine phosphateANDA2023-05-25
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
amebiasisEFO_0007144D000562A06
avian malariaD008289
discoid lupus erythematosusD008179L93.0
falciparum malariaEFO_0007444D016778B50
malariaEFO_0001068D008288B54
pemphigusEFO_1000749D010392L10
rheumatoid arthritisEFO_0000685D001172M06.9
systemic sclerodermaEFO_0000717D012595M34
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
P: Antiparasitic products, insecticides and repellents
P01: Antiprotozoals
P01B: Antimalarials
P01BA: Aminoquinoline antimalarials
P01BA01: Chloroquine
P01BB: Biguanide antimalarials
P01BB52: Chloroquine and proguanil
HCPCS
Code
Description
J0390
Injection, chloroquine hydrochloride, up to 250 mg
Clinical
Clinical Trials
156 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
MalariaD008288EFO_0001068B541051571247
Vivax malariaD016780EFO_0007445B517711428
Falciparum malariaD016778EFO_0007444B502886524
Covid-19D000086382U07.111075221
AnemiaD000740EFO_0004272D64.92125
Coronavirus infectionsD018352EFO_0007224B34.22214
Rheumatoid arthritisD001172EFO_0000685M06.92114
Asymptomatic diseasesD058070112
Sars-cov-2D000086402112
Glucosephosphate dehydrogenase deficiencyD005955EFO_0007287112
Show 6 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
GlioblastomaD005909EFO_00005152114
HivD006678O98.7123
Hiv infectionsD015658EFO_0000764B202113
CoronavirusD017934112
Sexually transmitted diseasesD012749A50-A6411
Sickle cell anemiaD000755EFO_0000697D57111
Chikungunya virusD00264611
PregnancyD011247EFO_0002950Z33.111
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Respiratory distress syndromeD012128EFO_1000637J8022
Brain neoplasmsD001932EFO_0003833C71112
PneumoniaD011014EFO_0003106J1811
Multiple myelomaD009101C90.011
Viral pneumoniaD011024EFO_0007541J12.911
Atrial fibrillationD001281EFO_0000275I48.011
GliomaD005910EFO_0000520111
CholangiocarcinomaD018281C22.1111
ChondrosarcomaD002813111
Breast neoplasmsD001943EFO_0003869C5011
Show 5 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Small cell lung carcinomaD05575222
GliosarcomaD01831611
PharmacokineticsD01059911
NeoplasmsD009369C8011
Pancreatic neoplasmsD010190EFO_0003860C2511
TuberculosisD014376EFO_0000774A15-A1911
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Psoriatic arthritisD015535EFO_0003778L40.511
ParasitemiaD01851211
HypertensionD006973EFO_0000537I1011
Prediabetic stateD011236EFO_1001121R73.0311
DyslipidemiasD050171HP_000311911
Metabolic syndromeD024821EFO_0000195E88.8111
OverweightD050177E66.311
FeverD005334HP_0001945R50.911
Birth weightD001724EFO_000434411
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCHLOROQUINE
INNchloroquine
Description
Chloroquine is an aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis. It has a role as an antimalarial, an antirheumatic drug, a dermatologic drug, an autophagy inhibitor and an anticoronaviral agent. It is an aminoquinoline, a secondary amino compound, a tertiary amino compound and an organochlorine compound. It is a conjugate base of a chloroquine(2+).
Classification
Small molecule
Drug class
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12
Identifiers
PDB4V2O
CAS-ID54-05-7
RxCUI2393
ChEMBL IDCHEMBL76
ChEBI ID3638
PubChem CID2719
DrugBankDB00608
UNII ID886U3H6UFF (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
MRGPRX1
MRGPRX1
PSAP
PSAP
Organism
Homo sapiens
Gene name
MRGPRX1
Gene synonyms
MRGX1, SNSR3, SNSR4
NCBI Gene ID
Protein name
mas-related G-protein coupled receptor member X1
Protein synonyms
G protein-coupled receptor MRGX1, G protein-coupled receptor SNSR3, Mas-related G protein-coupled receptor G2, MAS-related GPR, member X1, Sensory neuron-specific G-protein coupled receptor 3/4
Uniprot ID
Mouse ortholog
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 60,695 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
2,514 adverse events reported
View more details